On May 12, 2026 Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported that it will present data from multiple programs in its hematology portfolio, including an oral presentation of data from the RALLY-MF phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF), at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress, which will be held in Stockholm, Sweden on June 11-14, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to presenting an update from our RALLY-MF trial at EHA (Free EHA Whitepaper), highlighting consistently strong anemia response rates across MF subpopulations and background therapies" said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. "We will also present updates on our EPP program, including new data from the HELIOS open label extension study of bitopertin in EPP and data from the European cohort of the EPP LIGHT survey, ahead of the expected readout of the APOLLO Phase 3 trial of bitopertin in EPP later this year."
The oral presentation of data from the Phase 2 RALLY-MF study in patients with anemia of MF will cover N=61 patients with data through April 27, 2026. At the time of the abstract deadline, there were N=43 evaluable patients. Major response rates among evaluable patients at the abstract cutoff were 54% (15/28) for the non-transfusion dependent cohort, 67% (6/9) for the lightly transfused (TD Low) cohort, and 50% (3/6) for the heavily transfused (TD High) cohort. Overall response (major response + minor response) was 70%, with similar response regardless of concomitant JAK inhibitor therapy. Additional data and analyses will be included in the presentation at EHA (Free EHA Whitepaper).
Management will host a call following the EHA (Free EHA Whitepaper) meeting to review highlights of the presented data and next steps for the company on Monday, June 15 at 8:00am EDT. Please register for the event on the Events and Presentations page of Disc’s website (View Source).
Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide.
Details of Presentations and Abstracts:
DISC-0974 Oral Presentation:
Abstract Number: S306
Abstract Title: RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis
Session Title: S430 From erythropoiesis to transfusion practice
Session Details: Friday, June 12 (5:15pm – 6:30pm CEST / 11:15am – 12:30pm EDT)
Presenting Author: Naseema Gangat, M.B.B.S.
Bitopertin Abstracts:
Abstract Code: PS2394 (Poster Presentation)
Abstract Title: Additional safety and efficacy results from HELIOS: A phase 2, open-label, long-term extension study of bitopertin in erythropoietic protoporphyria
Session Details: Saturday, June 13 (6:45pm – 7:45pm CEST / 12:45pm – 1:45pm EDT)
Presenting Author: Amy Dickey, M.D., MSc
Abstract Code: PB4415 (Publication Only)
Abstract Title: Erythropoietic protoporphyria life impact and genetic health trajectory (EPP LIGHT) study: a cross-sectional survey of adults and adolescents in Europe
DISC-3405 Abstract:
Abstract Code: PF909 (Poster Presentation)
Abstract Title: RESTORE-PV – a phase 2 open-label study evaluating the safety and efficacy of the anti-TMPRSS6 monoclonal antibody DISC-3405 in participants with polycythemia vera
Session Details: Friday, June 12 (6:45pm – 7:45pm CEST / 12:45pm – 1:45pm EDT)
Presenting Author: Naseema Gangat, M.B.B.S.
(Press release, Disc Medicine, MAY 12, 2026, View Sourcenews-releases/news-release-details/disc-medicine-announces-multiple-presentations-across-3 [SID1234665534])